

# HCV: FROM SCREENING TO CURE, A BROAD PARTNERSHIP WITHIN A TOUGH BACKGROUND

Tournadre M<sup>1</sup>, Lesboueyries D<sup>1</sup>, Bellaïche G<sup>2</sup>, Touitou H<sup>3</sup>

<sup>1</sup> Harm Reduction's Center for Drugs' Users of the Association Aurore 93,

<sup>2</sup> Robert Ballanger Hospital's Division of Gastroenterology and Hepatology,

<sup>3</sup> Public Screening Center of the Department of Seine Saint Denis

## **Background:**

Our harm reduction's center for drugs' users is in the middle of parisian underprivileged suburbs, the most important drugs' trafficking, and a multicultural context where many passing through people are found. Most of them being unable to reach care, or running away from it, it's our priority to bring them to it. We chose to grow a broad partnership, because of the complexity of Hepatitis C, following every step and difficulty from screening to access to treatment.

## **Description of model of care/intervention:**

Our partnership :

- We got financial support in order to be trained to use rapid tests; indeed, we meet a population away from health services.
- Our partnership with medical divisions (located close to us) enable a fast and effective care
- This population's administrative status often being a brake, we work closely with a multidisciplinary system which, in addition to assisting people with complicated procedures using a team of mediators, help access to treatment along.
- At last, as many non-French speaking people are found, some users, who have been screened and/or taken care of before, can act as peer-leds' translators.

## **Effectiveness:**

300 to 400 drugs' users (80% intravenous) live around our center. In one year, 82 of them were screened. Among 47 who got a hcv-positive detection, at this time 11 could have access to HCV treatment, and 10 were cured.

## **Conclusion and next steps:**

The reality of HCV when it comes to drugs using is connected with many issues from different fields. Apart from the difficulties linked with substance using itself, our model of intervention made the screening and the access to hcv treatment faster and more frequent. The next steps will consist in developing peer-leds' system and our outreach work, meaning more marauding with a new partnership we are currently working on.

## **Disclosure of Interest Statement:**

*The conference collaborators recognise the considerable contribution that industry partners make to professional and research activities. We also recognise the need for transparency of disclosure of potential conflicts of interest by acknowledging these relationships in*

p  
u  
b  
l  
i  
c  
a  
t  
i  
o  
n  
s

a  
n  
d